PharmaShots

JUNE 23, 2023

Gilead Receives EMA’s CHMP Positive Opinion of Trodelvy (sacituzumab govitecan) for Pre-Treated HR+/HER2- Metastatic Breast Cancer Date: June 23, 2023 | Tags: Gilead, Trodelvy, sacituzumab govitecan, HR+/HER2- Metastatic Breast Cancer, Regulatory, EMA, CHMP, Positive Opinion Sarepta Therapeutics’ Elevidys Receives the US FDA’s Accelerated (..)

FDA 40

FDA 40

PharmaShots

APRIL 14, 2023

Ocugen Reports Preliminary Results from the P-I/II Trial of OCU400 for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis Date: Apr 14, 2023 | Tags: Ocugen, OCU400, Retinitis Pigmentosa, Leber Congenital Amaurosis, Clinical Trial, P-I/II Trial Candesant Biomedical Receives the US FDA Clearance of Brella SweatControl Patch for Primary (..)

FDA 40

FDA 40

Pharmaceutical Technology

APRIL 5, 2023

But access to these treatments continues to remain limited due to high price tags and variable availability across regions. More broadly however, several advancements are on the horizon for cell and gene therapies in 2023.

FDA 59

FDA Immunization 59

European Pharmaceutical Review

DECEMBER 27, 2023

Studies have since demonstrated significantly reduced CAR-associated CRS and other toxicities without jeopardising therapeutic yield and outcomes; 9 both G-CSF and tocilizumab are now part of daily practice in CART-cell therapy. This is in addition to its considerable price tag.

Adverse Reactions 93

Adverse Reactions Immunization Medical Schools Chemotherapy 93